Fixed- vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury

D. Green, M. Y. Lee, V. Y. Ito, T. Cohn, J. Press, P. R. Filbrandt, W. C. VandenBerg, G. M. Yarkony and P. R. Meyer Jr
Department of Medicine, Northwestern University Medical School, Chicago, IL.

Thromboembolism is a common and occasionally catastrophic complication in patients with spinal cord injury and complete motor paralysis. We, therefore, evaluated the efficacy and safety of two prophylactic regimens, using heparin in either fixed doses of 5000 U given subcutaneously twice daily or in doses adjusted to prolong the activated partial thromboplastin time (APTT) to approximately 1 1/2 times control. Patients were monitored with daily clinical examinations, serial impedance plethysmography, and Doppler flow studies. All events suspected to be thromboembolic were confirmed by venography, ventilation-perfusion scans, or pulmonary angiography. Seventy-five patients were randomized, and 58 (29 in each group) either remained in the study for more than seven weeks or experienced a thrombotic or hemorrhagic event. Patients on the adjusted-dose regimen received a mean (+/- SD) of 13,200 +/- 2200 U of heparin per dose and had an APTT 1 1/2 times higher than those on the fixed-dose regimen. Thromboembolism was detected in nine (31%) of 29 patients randomized to the fixed-dose regimen and two (7%) of 29 on the adjusted-dose regimen. While no patient who received the adjusted dose and whose APTT reached the target level had a thrombosis, bleeding occurred in seven patients. No patient on the fixed-dose regimen bled. We conclude that patients with spinal cord injury who can be maintained on doses of heparin sufficient to prolong their APTT to 1 1/2 times control values will be spared thromboembolic complications, but these patients are at high risk of bleeding, especially if they have trauma to other tissues in addition to their spinal cord injury.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT | FULL TEXT  

Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Geerts et al.
Chest 2008;133:381S-453S.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Levine et al.
Chest 2004;126:287S-310S.
ABSTRACT | FULL TEXT  

Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Geerts et al.
Chest 2004;126:338S-400S.
ABSTRACT | FULL TEXT  

Risk Factors for Venous Thromboembolism
Anderson and Spencer
Circulation 2003;107:I-9-16.
ABSTRACT | FULL TEXT  

Deep Vein Thrombosis and Its Prevention in Critically Ill Adults
Attia et al.
Arch Intern Med 2001;161:1268-1279.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant Treatment
Levine et al.
Chest 2001;119:108S-121S.
FULL TEXT  

Prevention of Venous Thromboembolism
Geerts et al.
Chest 2001;119:132S-175S.
FULL TEXT  

Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes
Zed et al.
Arch Intern Med 1999;159:1849-1857.
ABSTRACT | FULL TEXT  

Prospective Trial of Low-Molecular-Weight Heparin Versus Unfractionated Heparin in Moderately Injured Patients
Cohn et al.
VASC ENDOVASCULAR SURG 1999;33:219-223.
ABSTRACT  

Prevention and treatment of venous thromboembolism after major trauma
Verstraete
Trauma 1999;1:39-51.
ABSTRACT  

Low-Molecular-Weight Heparins
Weitz
NEJM 1997;337:688-699.
FULL TEXT  

Acute Spinal Injury
Weiss et al.
NEJM 1996;334:1747-1748.
FULL TEXT  

Management of Deep Vein Thrombosis and Pulmonary Embolism : A Statement for Healthcare Professionals From the Council on Thrombosis (in Consultation With the Council on Cardiovascular Radiology), American Heart Association
Hirsh and Hoak
Circulation 1996;93:2212-2245.
FULL TEXT  

Prevention of Venous Thromboembolism: An Update
Clagett
PERSPECT VASC SURG ENDOVASC THER 1994;7:71-84.
 

ADJUSTED-DOSE PROPHYLACTIC HEPARIN MORE EFFECTIVE BUT RISKY
JWatch General 1988;1988:3-3.
FULL TEXT